Monofree (Tropicamide)

Tropicamide blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary muscles. By competitively antagonising these receptors, it prevents acetylcholine‑driven contraction, causing the iris sphincter to relax and the pupil to enlarge, while also inhibiting ciliary muscle contraction, resulting in cycloplegia.

The dosing regimen for Monofree is determined by the prescribing clinician based on the specific examination or procedure. Typically, one or two drops are instilled in the conjunctival sac, but the exact number of drops, concentration, and timing are individualized and should follow the prescriber’s instructions.

Safety data for tropicamide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To request Monofree, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The most common alternative to tropicamide is phenylephrine, an adrenergic mydriatic. Phenylephrine dilates the pupil via alpha‑adrenergic stimulation, whereas tropicamide works by muscarinic antagonism. Tropicamide generally provides a faster onset and shorter duration of cycloplegia, while phenylephrine may produce a more pronounced dilation but lacks cycloplegic effect.

Monofree should be stored at room temperature, preferably below 25 °C, in its original container. Protect the solution from direct light, moisture and extreme temperature fluctuations. Keep the vial tightly sealed when not in use and discard any product that appears contaminated or discoloured.

Monofree is administered as an ocular drop. The prescribed number of drops is placed into the lower conjunctival sac of the target eye(s) using a sterile applicator. The patient should be instructed to avoid touching the tip of the bottle to the eye or surrounding tissues to maintain sterility.

The most serious adverse events include acute angle‑closure glaucoma, which can cause rapid intra‑ocular pressure rise, persistent mydriasis lasting beyond the expected period, and severe allergic reactions such as eyelid edema or conjunctival swelling. Immediate medical attention is required if any of these signs develop.

Monofree is contraindicated in individuals with known hypersensitivity to tropicamide or other anticholinergic agents, and it should be avoided in patients with narrow‑angle or uncontrolled glaucoma. Caution is also advised for patients with severe systemic anticholinergic sensitivity, such as those with urinary retention or certain cardiac conditions.